Yuyu Pharma, a global pharmaceutical company founded in Seoul, South Korea, announced on Wednesday that it has enroled the first patient in a phase two clinical study assessing YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties intended to treat patients with dry eye disease (DED).
The company has received approval from the United States Food and Drug Administration (FDA) for its Investigational New Drug Application (IND) for YP-P10 Ophthalmic Solution.
The approval enabled the company to start the phase two clinical study, named ICECAP (randomIzed plaCebo EffiCacy sAfety yP-p10), to assess the safety, tolerability, and efficacy of the product to help advance the treatment of patients with DED. The study is to be carried out in the United States at seven sites with 240 patients. The product has been developed by Yuyu Pharma R&D.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP